J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Poggi, J. C.
Right arrow Articles by Reis, M. L. d.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Poggi, J. C.
Right arrow Articles by Reis, M. L. d.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

CLINICAL STUDIES

Pharmacodynamics, Chiral Pharmacokinetics, and Pharmacokinetic-Pharmacodynamic Modeling of Fenoprofen in Patients With Diabetes Mellitus

Josiane Cristófani Poggi, Giuliano Rodrigo Barissa, Eduardo Antônio Donadi, Milton Cesar Foss, Fernando de Queiróz Cunha, Vera Lucia Lanchote and Marina Lemos dos Reis

From the Faculdade de Ciências Farmacêuticas de Ribeirão Preto-Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil (Dr Poggi, Dr Barissa, Dr Lanchote, Dr Lemos dos Reis); Faculdade de Medicina de Ribeirão Preto-Universidade de São Paulo, Ribeirão Preto, São Paulo, Brazil (Dr Donadi, Dr Foss, Dr de Queiróz Cunha).

The objective of the present study was to assess the influence of type 1 and type 2 diabetes mellitus on the enantioselective pharmacodynamics and pharmacokinetics of fenoprofen. Patients with diabetes mellitus type 1 (n = 7) or type 2 (n = 7) and healthy volunteers (n = 13) received orally a single 600-mg dose of racemic fenoprofen. Monocompartmental analysis of (+)-(S)-fenoprofen showed a significant difference (P < .05, Kruskal-Wallis test) in area under the curve (AUC) values (153.68 vs 243.50 µg·h/mL) and oral clearance (1.95 vs 1.23 L/h) only between patients with diabetes mellitus type 2 and healthy volunteers. The inhibitory activity of cyclooxygenases was evaluated indirectly by the determination of prostaglandin E2 (COX-2) and thromboxane B2 (COX-1) using the sigmoidal inhibitory Emax model. The patients with type 2 diabetes mellitus presented lower IC50 (3.29 vs 6.0 µg/mL) and g (0.73 vs 2.01) values for COX-1 activity compared to healthy volunteers (P < .05, Kruskal-Wallis test). These results show that diabetes mellitus type 2, but not type 1, influences the pharmacokinetics and pharmacodynamics of (+)-(S)-fenoprofen.

Key Words: Diabetes • fenoprofen • pharmacokinetics • pharmacodynamics • enantiomers

Address for reprints: Marina Lemos dos Reis, Faculdade de Ciências Farmacêuticas de Ribeirão Preto-USP, Departamento de Física e Química, Avenida do Café s.n. Campus da USP, 14040-903. Ribeirão Preto, São Paulo, Brazil; e-mail: mldreis{at}fcfrp.usp.br.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology